INmune: maintaining timeline to successfully conclude Alzheimr's trial amid hold

 Enrollment in the Company’s Phase II study using XProTM to treat patients with Alzheimer’s Disease with neuroinflammation is accelerating in sites outside the US and the Company is maintaining its timeline to successfully conclude the trial.

In the US, the previously identified clinical hold issues have been successfully addressed however the Phase II study remains on clinical hold pending additional information on long-term stability which the Company will provide before the end of 2023.

https://www.globenewswire.com/news-release/2023/12/18/2798118/0/en/INmune-Bio-Provides-Update-Regarding-Global-Alzheimer-s-Phase-II-Clinical-Trial-and-Clinical-Hold-Issued-by-the-United-States-FDA.html